Afficher la notice abrégée

Tumor fraction-based prognostic tool for cancer patients referred to early phase clinical trials

dc.rights.licenseopenen_US
dc.contributor.authorBAYLE, Arnaud
dc.contributor.authorBELCAID, Laila
dc.contributor.authorCOUSIN, Sophie
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorTRIN, Kilian
dc.contributor.authorALAME, Melissa
dc.contributor.authorROULEAU, Etienne
dc.contributor.authorSOUBEYRAN, Isabelle
dc.contributor.authorLACROIX, Ludovic
dc.contributor.authorBLOUIN, Laura
dc.contributor.authorVASSEUR, Damien
dc.contributor.authorCROMBE, Amandine
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMATHOULIN PELISSIER, Simone
IDREF: 071358587
dc.contributor.authorSORIA, Jean-Charles
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBELLERA, Carine
dc.contributor.authorITALIANO, Antoine
dc.date.accessioned2024-12-06T09:21:23Z
dc.date.available2024-12-06T09:21:23Z
dc.date.issued2024-10-07
dc.identifier.issn2397-768Xen_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/203720
dc.description.abstractEnSelecting patients for phase I cancer trials is crucial to ensure a sufficient life expectancy. Frail patients, better suited for palliative care, should not be exposed to new drugs with minimal benefit. Enrolling patients at high risk of early death can jeopardize the study. Our analysis of two large precision medicine studies used tumor fraction from ctDNA to develop a predictive model, demonstrating notable predictive accuracy and aiding in patient selection.
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.title.enTumor fraction-based prognostic tool for cancer patients referred to early phase clinical trials
dc.title.alternativeNPJ Precis Oncolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1038/s41698-024-00685-9en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed39375508en_US
bordeaux.journalnpj Precision Oncologyen_US
bordeaux.page227en_US
bordeaux.volume8en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue1en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamEPICENE_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDFondation Bergoniéen_US
bordeaux.identifier.funderIDFondation Gustave Roussyen_US
hal.identifierhal-04822574
hal.version1
hal.date.transferred2024-12-06T09:21:26Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=npj%20Precision%20Oncology&rft.date=2024-10-07&rft.volume=8&rft.issue=1&rft.spage=227&rft.epage=227&rft.eissn=2397-768X&rft.issn=2397-768X&rft.au=BAYLE,%20Arnaud&BELCAID,%20Laila&COUSIN,%20Sophie&TRIN,%20Kilian&ALAME,%20Melissa&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_NPJPrecisOncol_2024_Bayle.pdf
Taille:
674.8Ko
Format:
PDF
Voir/Ouvrir
Thumbnail
Nom:
license_rdf
Taille:
811octets
Format:
application/rdf+xml
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée